Priority review for Tibotec’s HIV drug etravine
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA grants priority review to Tibotec's NDA for etravine (TMC125), setting the review clock for a Jan. 18, 2008, user fee date. The non-nucleoside reverse transcriptase inhibitor was the first in the class to show antiviral activity in patients with documented NNRTI resistance, according to the Ortho Biotech subsidiary. The NDA is supported by two Phase III 24-week randomized, double-blinded, placebo-controlled trials - DUET-1 and DUET-2 - that compared the agent in combination with other antiretroviral agents in treatment-experienced HIV-1 patients. TMC125 is currently available through an expanded access program in the U.S., Europe and Canada for HIV-1 infected adults who have experience with each of three major oral classes of ARVs (NRTIs, NNRTIs and protease inhibitors), are unable to use currently approved NNRTIs due to resistance/intolerance and have received at least two PI-based regimens...
You may also be interested in...
Tibotec Intelence Not For First-Line Use, FDA Says; Is Follow-On Naive?
The drug interaction profile of Johnson & Johnson subsidiary Tibotec’s antiretroviral Intelence (etravirine) precludes its first-line use against HIV, leaving open a therapeutic niche that Tibotec hopes to fill with another non-nucleoside reverse transcriptase inhibitor, TMC278.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.